NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,003 DKK | -0.44% |
|
+0.89% | +43.62% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.62% | 64TCr | |
| +55.21% | 81TCr | |
| -7.01% | 35TCr | |
| +18.13% | 33TCr | |
| +8.72% | 30TCr | |
| +16.30% | 25TCr | |
| +2.41% | 22TCr | |
| +12.47% | 22TCr | |
| +8.48% | 17TCr | |
| -3.73% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Confirms WHO Coordination Amid Fake Ozempic Batches
